$IPSC

Russotti Gregory sold $1K of IPSC

Russotti Gregory (See Remarks) sold 524 shares of Century Therapeutics, Inc. (IPSC) at $2.11 on 2026-06-08.

Original reporting
SEC EDGAR · Russotti Gregory
Published Jun 9, 2026, 8:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 9, 2026, 8:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$IPSC
Bearish
medium confidence
Mentioned
$IPSC
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IPSCBearishLow
01

Why it matters

Because it is a small, routine insider sale and not tied to a new corporate event, it is unlikely to drive fundamental repricing.

02

Market read

Traders may note marginal sentiment impact, but the disclosure is not a new fundamental catalyst.

03

What to watch

The article does not state a 10b5-1 plan and provides only a small sale size, limiting inference about future insider behavior.

Relevance 3/10Novelty 2/10Timing: filed 2026-06-09 (covers sale dated 2026-06-08)

Background

The article is an SEC EDGAR Form 4 disclosure of an officer’s open-market sale in Century Therapeutics, Inc.

Company-level read

Ticker impact

$IPSCBearishMedium confidence
Context

Century Therapeutics (IPSC) disclosed an officer open-market sale of 524 shares at $2.1110 on 2026-06-08 via SEC Form 4.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment/flow.

Evidence & confidence

The filing is a Form 4 insider transaction (open-market sale) with ~$1.1K proceeds and no 10b5-1 plan stated; such prints are typically not material to valuation.

Market effects

No sector read-through; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Insider sales can be non-informational (taxes, diversification) and may not reflect a change in outlook.

Key entities

  • Century Therapeutics, Inc.

    Company whose officer disclosed an open-market sale of shares via SEC Form 4.

  • Russotti Gregory

    Officer who sold 524 shares on 2026-06-08.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IPSCMedAI 8/10

Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026

Century Therapeutics, Inc. (IPSC) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026 Data demonstrated scalable production, in vivo function and immune evasion, and updated progress toward clinical dosing of CNTY-813, Centur

$IPSCMedAI 8/10

Century Therapeutics presents diabetes therapy data at EASD

Century Therapeutics (NASDAQ:IPSC) presented data on CNTY-813, a diabetes therapy, at the EASD meeting. The therapy showed long-term glycemic control in mouse models and successful engraftment in rats. The company plans to submit an IND application in Q4 2026, with clinical data expected in H2 2027, according to the press release.

$IPSCMed

Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026

Century Therapeutics (NASDAQ: IPSC) presented nonclinical data for CNTY-813, its iPSC-derived islet replacement therapy for type 1 diabetes, at EASD 2026. Data showed glycemic control in diabetic mice, scalable production, and immune evasion. The company expects to submit an IND application in Q4 2026 and anticipates initial clinical data in 2H 2027.

$IPSCHighAI 8/10

Century Targets FDA Filing for Diabetes Cell Therapy

Century Therapeutics (NASDAQ: IPSC) aims to file for FDA approval of its diabetes cell therapy, CNTY-813, in Q4 2026, with initial human data expected in 2027. The company reported $197.2M in cash as of Q2 2026, sufficient to fund operations into Q1 2029. Preclinical results showed promising glucose control and immune evasion, but clinical outcomes are not guaranteed. Century also advances CNTY-308, a CAR-iT cell therapy, with IND-enabling work on track for 2026. Q2 R&D expenses decreased 27% to